• 首页
  • 创刊词
  • 期刊介绍
    • 杂志简介
    • 编委会
    • 编辑部
  • 过刊浏览
  • 杂志订阅
    • 订阅须知
    • 在线订阅
  • 在线投稿
    • 投稿指南
    • 年度选题
    • 在线投稿
  • 下载中心
  • 学术交流
    • 研究论坛
    • 学术沙龙
    • 编委会会议
  • 登录
    • 作者登录
    • 审稿登录
    • 编辑登录
    • 读者登录
引用本文:陈童, 蒋蓉, 邵蓉.加拿大药品返利协议研究及对我国的启示[J].中国卫生政策研究,2021,14(4):68-73
加拿大药品返利协议研究及对我国的启示
投稿时间:2021-01-30  修订日期:2021-04-09  PDF全文浏览  HTML全文浏览
陈童, 蒋蓉, 邵蓉
中国药科大学国家药物政策与医药产业经济研究中心 江苏南京 211198
摘要:目的:通过介绍泛加拿大制药联盟谈判药品返利协议的签订机制,分析协议条款构成、价格保密设定方式和协议执行方式,为我国医保谈判药品的价格保密协议制定提供借鉴。方法:运用文献研究和政策分析法,对加拿大药品返利协议的签订流程、协议条款内容、价格保密机制进行梳理与分析。结果:加拿大药品谈判协议以返利的方式形成机密折扣,有效平衡了制药企业和医保支付方的利益。结论:我国医保谈判药品价格保密协议处于起步阶段,可借鉴加拿大的做法,借助返利的形式建立谈判药品价格保密机制,并辅以相应的配套措施如规范谈判协议格式和引入第三方评估机构,从而提高药品降价的科学性和合理性。
关键词:加拿大  返利协议  价格保密  产品收录协议  意向书
基金项目:国家社会科学基金重大项目(15ZDB167)
Research on the Canadian Pharmaceutical Rebate Agreements and its enlightenment to China
CHEN Tong, JIANG Rong, SHAO Rong
The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing Jiangsu 211198, China
Abstract:Objective: To introduce the contract signing mechanism, agreement terms, methods for price confidentiality and implementing of rebate agreements negotiated through Pan-Canadian Pharmaceutical Alliance, and to provide reference for the formulation of China' price confidentiality agreements of negotiated drugs. Methods: Intensive literature research and policy analysis were used to analyze the negotiation process, terms and price secrecy mechanism of the Canadian drug rebate agreements. Results: Through rebate agreements, Canada has achieved the right balance of interests between pharmaceutical companies and medical insurance payers. Conclusion: In its initial status today, China' medical insurance drug price confidentiality agreement is still in its earlier stages and can learn from Canada' practice. This can only be achieved by using the form of rebates to establish drug price secrecy mechanism, supplemented by corresponding supporting measures such as standardizing negotiation agreements format and introducing third-party evaluation agencies, thereby improving the scientific nature and rationality of drug price reduction.
Key words:Canada  Rebates agreements  Price confidentiality  Product Listing Agreement  Letter of Intent
摘要点击次数: 1416    全文下载次数: 713
版权所有:《中国卫生政策研究》编辑部
您是本站第61968628位读者 今日访问2444次
京ICP备10218182号-6

京公网安备 11010502037852号